Mounjaro Prices in September: the Facts Behind the Rise

Why September 2025 reset Mounjaro's UK price

Eli Lilly's decision to raise Mounjaro's UK list price from 1 September 2025 was widely reported and, as the coverage of the September rise made clear, it was substantial. The jump from roughly £122 to roughly £330 at the highest dose is not a rounding error or a pharmacy markup. It reflects Eli Lilly reanchoring the medicine's value in the UK market after an extended introductory pricing period. Private providers had to absorb or pass on that change; most passed it on. Typical private prices since September range roughly £149 to £375 per month depending on dose and provider, though these figures are reported estimates and vary. The reasons behind the September increase do not make the medicine more or less effective, SURMOUNT-1 demonstrated around 20 to 21 percent average body-weight reduction at the 15mg dose over 72 weeks, a result that stands regardless of what the pen costs as reported in the New England Journal of Medicine. But the price change matters to patients comparing options, which is why it deserves a straight answer rather than a marketing gloss.

What headline prices for Mounjaro often leave out

A quoted monthly figure rarely tells the whole story. Across the private market, many advertised prices cover the medicine alone. Clinical consultation fees, prescription charges, delivery costs and ongoing dose-review support can each appear as separate line items, sometimes discovered only at checkout. That structure is legal, but it makes like-for-like comparison genuinely difficult. If you are working out what Mounjaro actually costs in September for your circumstances, the honest question to ask any provider is: what does your quoted price include? A lower headline number that adds a consultation fee and a delivery charge can easily exceed a higher all-in figure. It is also worth noting that Mounjaro is a Prescription-Only Medicine; under UK law, a prescriber must assess your suitability before any pharmacy can dispense it. That clinical step is not optional overhead that a cheaper provider has cleverly removed, it is a legal requirement. The MHRA's warnings about counterfeit weight-loss pens are partly rooted in exactly this: sellers offering these medicines at dramatically low prices, without a prescription or clinical assessment, are operating outside the law and the supply chain.

What the price includes at nume, and what it does not

We are not the cheapest option in the market. That is a deliberate choice, not an oversight. One transparent price at nume covers the clinical consultation, the prescription, the medicine and free next-working-day delivery, tracked through DPD, your pen arrives in a plain, unbranded box, with no indication of what is inside. There is no subscription, no auto-renewal, and no hidden fee that surfaces at checkout. Every repeat order goes back to a real prescriber for clinical re-review; no software wave-through. You can read more about how Mounjaro is priced at nume and what the full process involves on our dedicated pricing page. For context on the specific September threshold and what it changed, the 1 September pricing detail sets it out clearly. If you are starting on the lowest dose, our Mounjaro 5mg price match explains how we approach pricing at that starting point. Our pharmacy is registered with the GPhC (premises number 9012878, verifiable on the GPhC register) and we source Mounjaro through the licensed UK supply chain via Eli Lilly's authorised UK route.

Why the cheapest listing is the wrong measure for a prescription medicine

Price is a reasonable thing to care about. Over a year of treatment, even modest monthly differences add up. But for a Prescription-Only Medicine, the cheapest listing answers the wrong question. The right question is whether the clinical assessment is genuine, whether the supply chain is verified, and whether there is a qualified prescriber accountable for your care. The NHS's guidance on tirzepatide makes clear that this is a medicine requiring individual clinical assessment, the prescriber weighs your health history, any current medicines, and your weight-related conditions before deciding whether and at what dose to proceed. None of that is replicated by a fast checkout form and an unlicensed seller. A saving of £20 a pen is not a saving if the pen is counterfeit, underdosed, or dispensed without proper oversight. Our full Mounjaro overview covers the clinical side in more depth, and if you are ready to find out whether treatment is suitable for you, our prescribers review consultations the same day, a real clinician reads your answers, not an automated process.